Home › Blog › Weight Loss › Mounjaro vs Wegovy UK

Mounjaro vs Wegovy UK 2026: The Complete Clinical Comparison — Efficacy, Cost, Side Effects and Who Should Choose Which

Overview: Mounjaro vs Wegovy in 2026

Mounjaro (tirzepatide) and Wegovy (semaglutide) are the two most clinically significant weight loss medications in the UK. Both are prescription-only. Both are once-weekly injections. Both have transformed the clinical management of obesity. And both are available at Slinic right now.

The question of which is better is not simple — and any guide that gives you a one-line answer is oversimplifying a clinical decision that depends on your individual circumstances. This guide gives you the complete picture: the mechanisms, the trial data, the head-to-head evidence, the cost comparison, the side effects, and a clinical decision framework that helps you and your Slinic prescriber arrive at the right choice for you.

Mechanism: How Mounjaro and Wegovy Work Differently

The clinical difference between Mounjaro and Wegovy starts at the molecular level — and understanding the mechanism explains why the trial results differ.

Wegovy (semaglutide): GLP-1 receptor agonist

Wegovy activates GLP-1 (glucagon-like peptide-1) receptors — the same pathway used by the gut hormone GLP-1, which is naturally released after eating to signal fullness, slow gastric emptying, and stimulate insulin release. By activating this pathway continuously at a higher level than natural GLP-1, Wegovy produces sustained appetite suppression and the metabolic changes that drive weight loss.

Mounjaro (tirzepatide): Dual GIP + GLP-1 receptor agonist

Mounjaro activates two hormone receptor pathways simultaneously — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a second gut hormone that was previously less well understood in the context of obesity. Its addition to GLP-1 agonism produces a synergistic effect: greater appetite suppression, more pronounced metabolic benefit, and — in clinical trials — meaningfully greater weight loss. For a detailed explanation of how this dual mechanism works, see our guide to how Mounjaro works for weight loss.

Efficacy: The Full Trial Data Compared

No comparison of Mounjaro and Wegovy is complete without the full trial data. Here is every relevant result from the landmark trials.

SURMOUNT-1 (Mounjaro) vs STEP 1 (Wegovy 2.4mg)

STEP UP trial: Wegovy 7.2mg

Published in the Lancet Diabetes & Endocrinology in 2025, the STEP UP trial evaluated a higher Wegovy dose — 7.2mg — in adults with obesity. Results were substantially better than the 2.4mg standard dose:

The 7.2mg dose was MHRA approved in January 2026 and is available at Slinic. The MHRA approval of the Wegovy pill (oral semaglutide) on 11 June 2026 adds a further dimension — see our Wegovy pill guide.

The NEJM 2025 Head-to-Head Trial: Tirzepatide vs Semaglutide Directly Compared

The most important clinical development in this comparison is the 2025 head-to-head trial published in the New England Journal of Medicine — the first randomised trial to directly compare tirzepatide and semaglutide for obesity treatment.

This is a landmark study because it removes the need to compare data from separate trials with different patient populations and protocols. The question “is Mounjaro better than Wegovy?” now has a direct, randomised clinical trial answer.

Trial design

The SURMOUNT-5 trial randomised adults with obesity (BMI ≥30 or ≥27 with comorbidities) to receive tirzepatide or semaglutide 2.4mg weekly. Both medications were dose-escalated per their standard protocols over 72 weeks alongside lifestyle support. This is as close to a fair head-to-head comparison as a clinical trial can produce.

Results

The Wegovy 7.2mg Dose: Has It Closed the Gap?

The MHRA approval of Wegovy 7.2mg in January 2026 significantly changed the Mounjaro vs Wegovy comparison. Before the 7.2mg dose, Mounjaro at 22.5% and Wegovy at 14.9% represented a substantial efficacy gap. The 7.2mg dose producing 20.7% average weight loss has narrowed that gap considerably.

For a complete guide to the 7.2mg dose see our Wegovy 7.2mg guide.

What the narrowed gap means clinically

At maximum licensed doses — Mounjaro 15mg (22.5%) vs Wegovy 7.2mg (20.7%) — the difference is approximately 1.8 percentage points. For a patient starting at 100 kg:

• Mounjaro 15mg average: 22.5 kg lost
• Wegovy 7.2mg average: 20.7 kg lost
• Difference: approximately 1.8 kg

That is a genuine clinical difference — but not the dramatic gap that existed before the 7.2mg approval. The cost difference between Mounjaro maintenance (£285/pen) and Wegovy 2.4mg maintenance (£209.99/pen) may now be a more significant practical consideration for some patients than the efficacy difference at maximum doses.

Real Weight Loss in Kilograms: Mounjaro vs Wegovy Side by Side

All figures based on published trial averages. Individual results vary significantly.

Side Effects: Mounjaro vs Wegovy Compared

The side effect profiles of Mounjaro and Wegovy are broadly similar because both activate GLP-1 receptors — the primary driver of gastrointestinal side effects. The differences are subtle but clinically meaningful for some patients. For comprehensive management guidance see our Mounjaro side effects guide.

Key difference: Dysaesthesia

The most clinically significant side effect difference is dysaesthesia — a sensation of abnormal tingling, numbness, or altered skin perception — which affects 22.9% of patients on Wegovy 7.2mg but is not a recognised side effect of Mounjaro at standard doses. For patients who find this tolerable (85.7% of cases resolved while continuing treatment in STEP UP), it is manageable. For patients who cannot tolerate it, Mounjaro at the equivalent efficacy level may be the better choice.

Key difference: GI rates at 7.2mg

The 7.2mg Wegovy dose produces higher total GI event rates (70.8%) than Mounjaro 15mg (~50%). For patients with a history of GI sensitivity, this is a clinical consideration favouring Mounjaro.

What is the same

The absolute contraindications are essentially identical — both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2, both carry a pancreatitis risk (following the MHRA January 2026 update), and both require discontinuation before conception. Discontinuation rates due to side effects are similar across both medications.

Dosing Schedules: Mounjaro vs Wegovy

Key practical difference: Mounjaro reaches its maximum dose in 5 months with consistent escalation. Wegovy reaches its standard maintenance dose in 4 months — but the 7.2mg step-up comes later, after a plateau at 2.4mg. This means patients on Wegovy who want maximum efficacy may be on treatment for 6–8 months before reaching the dose that produces 20.7% average weight loss. For a complete guide see our Mounjaro dosing guide.

Full UK Pricing Comparison: Mounjaro vs Wegovy at Slinic

Both medications are available at Slinic at fixed 2026 prices with no subscription and no minimum term. Here is the complete side-by-side price comparison at every dose.

All prices + £4.99 delivery. No subscription. Free monthly check-in. Needles included. Subject to clinician approval. Prices correct June 2026.

Annual cost comparison at Slinic

For the full cost breakdown see our Mounjaro cost guide and our cheapest Mounjaro UK guide.

NHS Access: Mounjaro vs Wegovy

Cardiovascular Evidence: Wegovy Has the Edge

This is the one area where Wegovy currently has a meaningful clinical advantage over Mounjaro — and it matters particularly for patients with existing cardiovascular disease.

Wegovy: Formal cardiovascular benefit on UK licence label

The SELECT trial showed that Wegovy reduced major adverse cardiovascular events by 20% in adults with existing cardiovascular disease, overweight or obesity, and no type 2 diabetes. This result — a 20% reduction in heart attack, stroke, and cardiovascular death — earned Wegovy a formal cardiovascular benefit statement on its UK licence label. This makes Wegovy the only UK-licensed weight loss injection with this specific label claim.

Mounjaro: Positive signals but not yet labelled

Mounjaro’s cardiovascular outcomes programme (SURPASS-CVOT) showed positive signals and the SURMOUNT-1 trial showed meaningful improvements in cardiometabolic risk markers. However, Mounjaro does not yet have a formal cardiovascular benefit on its UK licence label. The formal cardiovascular outcomes trial results are anticipated in 2026–2027.

Contraception Interaction: An Important Difference

This is a difference between the two medications that is frequently overlooked — and it matters for patients of reproductive age on oral contraception.

Mounjaro: Important interaction warning

The MHRA Drug Safety Update (January 2025) confirmed that Mounjaro may reduce the effectiveness of oral contraceptive pills by slowing gastric emptying and altering absorption. Patients taking the combined pill must use an additional barrier method for at least four weeks after starting Mounjaro and after each dose increase. See our Mounjaro and contraception guide for full detail.

Wegovy injection: No equivalent warning for the injection

The injectable Wegovy does not carry the same oral contraceptive absorption warning as Mounjaro. The Wegovy injection bypasses the gastrointestinal tract and therefore does not affect oral contraceptive absorption. For patients who take the oral contraceptive pill and cannot or do not want to use additional contraception, the Wegovy injection may be preferable to Mounjaro on this basis alone.

The Wegovy Pill: A New Dimension to This Comparison

The MHRA approval of the Wegovy pill (oral semaglutide 25mg) on 11 June 2026 adds an entirely new dimension to the Mounjaro vs Wegovy comparison. For the first time, patients have the option of an oral semaglutide treatment rather than an injection — and this may be decisive for needle-phobic patients.

Who Should Choose Which: The Clinical Decision Framework

This is the section that the comparison guides that rank above this one consistently get wrong — they hedge everything and tell patients to “ask their prescriber.” Here is the honest clinical framework that Slinic’s prescribers actually use.

Choose Mounjaro if:

• Your primary goal is maximum weight loss — Mounjaro produces greater average weight loss in all available evidence including the head-to-head NEJM trial
• You have type 2 diabetes or insulin resistance — Mounjaro’s dual GIP+GLP-1 mechanism produces superior glycaemic control alongside weight loss
• You have previously tried semaglutide (Wegovy or Ozempic) and achieved sub-optimal results — Mounjaro’s different mechanism may produce a better response
• You are not on the oral contraceptive pill — or you are willing to use additional contraception during treatment
• Side effects from nausea and vomiting are a primary concern — Mounjaro’s rates are modestly lower than Wegovy’s at equivalent doses
• You find the idea of dysaesthesia (tingling) at higher doses particularly concerning

Choose Wegovy if:

• Cost is a significant factor — Wegovy is meaningfully cheaper at every dose stage; £75–£110/month less than Mounjaro at equivalent stages
• You have existing cardiovascular disease — Wegovy has a formal cardiovascular benefit on its UK licence label; Mounjaro does not yet
• You are on the oral contraceptive pill and do not want to use additional contraception
• You previously tried Mounjaro and experienced poor tolerability — Wegovy’s GLP-1-only mechanism may be better tolerated for some patients
• You are satisfied with 14.9–20.7% average weight loss and value the lower cost
• You want the medication with the longest real-world safety track record in weight management

Choose the Wegovy pill (coming soon at Slinic) if:

• You are needle-phobic — the only truly needle-free semaglutide option
• You travel frequently — no refrigeration, no sharps in luggage
• You cannot manage the injection technique reliably
• You can consistently maintain the fasting protocol (no food, coffee, or other medications for 30 minutes after taking)

Switching Between Mounjaro and Wegovy

Some patients start on one medication and switch to the other — either due to cost, side effects, or suboptimal results. Both directions of switching are clinically possible. See our complete Mounjaro to Wegovy switching guide for the clinical protocol.

Switching from Mounjaro to Wegovy

• No washout period required — GLP-1 medications can be switched directly
• Start Wegovy at the 0.25mg initiation dose regardless of Mounjaro dose reached — the dosing scales and receptor sensitivities are different
• Expect a brief escalation period before reaching therapeutic efficacy with the new medication
• Most common reason: cost reduction after achieving initial significant weight loss

Switching from Wegovy to Mounjaro

• No washout period required
• Start Mounjaro at 2.5mg initiation dose
• Many patients who switch from Wegovy to Mounjaro after a plateau find that weight loss restarts — the dual mechanism produces a response when GLP-1-only therapy has reached its ceiling
• Discuss the oral contraceptive interaction change with your Slinic clinician if relevant

What Comes Next: Beyond Mounjaro and Wegovy

The Mounjaro vs Wegovy comparison dominates UK weight loss conversations in 2026 — but both may be overtaken by the next generation. For patients thinking longer-term:

• Retatrutide — Eli Lilly’s triple GLP-1/GIP/glucagon agonist. TRIUMPH-1 Phase 3 results (May 2026): 28.3% average weight loss. UK availability expected 2027–2028.
• Orforglipron (Foundayo) — Eli Lilly’s daily oral GLP-1 pill. FDA approved April 2026. No fasting protocol. 12.4% average weight loss. UK expected late 2026.
• Wegovy pill — MHRA approved 11 June 2026. Oral semaglutide, 16.6% average weight loss. Coming to Slinic within weeks.

Practical Differences: Storage, Travel and Daily Life

Beyond efficacy and cost, there are practical differences between Mounjaro and Wegovy that affect daily life — particularly for patients who travel frequently or have specific lifestyle considerations.

Wegovy’s longer room temperature window (6 weeks vs 21 days for Mounjaro) is a modest practical advantage for patients who travel extensively. For cold-chain delivery to your UK address, both medications arrive identically from Slinic in certified cold-chain packaging.

The Honest Summary: Which One Wins?

As a pharmacist who prescribes both every day, I am often asked for a simple answer. Here is my honest clinical summary.

On pure weight loss efficacy: Mounjaro wins. Every trial shows greater average weight loss. The head-to-head NEJM trial confirms it directly. The difference at maximum doses — 22.5% vs 20.7% — is modest but real.

On cardiovascular evidence: Wegovy wins. The SELECT trial data and the formal cardiovascular benefit label are meaningful advantages for patients with existing heart disease. Mounjaro’s cardiovascular data is promising but not yet labelled.

On cost: Wegovy wins clearly. Approximately £75–£110/month cheaper at equivalent maintenance doses at Slinic. Nearly £1,000 less per year. For most patients, this is a significant consideration.

On side effects: Essentially equal. Mounjaro’s rates are slightly lower at some comparable doses. Wegovy 7.2mg produces higher GI event rates and dysaesthesia that Mounjaro does not. For most patients, tolerability is similar.

On oral option: Wegovy wins. The Wegovy pill gives semaglutide patients a needle-free alternative. Mounjaro remains injection-only until orforglipron (Foundayo) provides Eli Lilly’s oral GLP-1 option — though at lower efficacy.

For most patients without a specific cardiovascular, contraceptive, or cost reason to choose Wegovy: Mounjaro is the stronger clinical choice. For patients where cost is a significant factor, who have existing cardiovascular disease, or who are on oral contraception: Wegovy is an excellent and often preferable alternative.

At Slinic, your free clinical assessment is where this decision gets made properly — with your medical history, your goals, your budget, and your individual circumstances all factored in by a registered prescriber with 25 years of clinical experience.

Deep Dive: Why the Dual Mechanism Matters So Much

Most comparisons of Mounjaro and Wegovy note that Mounjaro acts on two receptors while Wegovy acts on one — and leave it there. Understanding why the addition of GIP receptor activation produces such substantially better outcomes requires a slightly deeper look at the pharmacology.

The GIP receptor: what it actually does

GIP (glucose-dependent insulinotropic polypeptide) was, until recently, considered primarily as a diabetes-relevant hormone. Its role in obesity was poorly understood. The development of tirzepatide forced a re-evaluation of GIP’s metabolic significance.

GIP receptor activation in fat tissue (adipocytes) appears to enhance the body’s response to GLP-1 signalling in a synergistic rather than simply additive way. There are several proposed mechanisms:

• Enhanced insulin sensitivity in fat tissue — GIP promotes healthy fat storage during caloric surplus and fat mobilisation during deficit, improving the metabolic efficiency of weight loss
• Amplified appetite suppression — GIP activation in the central nervous system appears to enhance the satiety signal already produced by GLP-1 receptor activation
• Improved beta-cell function — particularly relevant for patients with type 2 diabetes or insulin resistance, where pancreatic beta cell health has been compromised
• Reduced GI side effects — paradoxically, dual GIP+GLP-1 activation appears to reduce the gastrointestinal side effect burden compared with high-dose GLP-1-only activation. This may explain why Mounjaro’s GI side effect rates are modestly lower than Wegovy 2.4mg’s, despite producing greater average weight loss

The synergistic effect — rather than simple addition — is why tirzepatide at 15mg produces 22.5% average weight loss while semaglutide at its equivalent maximum dose produces 14.9–20.7% depending on which dose you use. It is not simply that Mounjaro has two mechanisms where Wegovy has one — it is that the two mechanisms amplify each other’s effects in a way that exceeds what either would produce alone.

Long-Term Data: What Happens at 18 Months and Beyond

Both the SURMOUNT and STEP trial programmes include extension data that helps answer the most important long-term question: does weight loss plateau, and what happens when treatment stops?

Mounjaro long-term: SURMOUNT-4

SURMOUNT-4 — the long-term extension trial — followed patients for 88 weeks. Results showed that weight loss continued to accumulate without a clear plateau at maintenance dose throughout the extension period. Patients who stopped tirzepatide after 36 weeks of maximum-dose treatment and received placebo for the remaining 52 weeks regained approximately two-thirds of their lost weight. This confirms that the biological drivers of obesity persist and that the benefits of tirzepatide require continued treatment to be maintained.

Wegovy long-term: STEP 4 extension

Similar findings for semaglutide — continued treatment maintained weight loss; withdrawal led to significant regain. The SELECT trial follow-up confirmed sustained cardiovascular benefit with continued treatment.

What this means for long-term treatment decisions

Both medications require ongoing use to maintain weight loss — a finding consistent across the GLP-1 class. This is important context for annual cost calculations. Long-term maintenance on either medication is clinically appropriate for most patients — similar to how anti-hypertensive medication is continued long-term rather than stopped when blood pressure normalises.

For guidance on managing long-term treatment, pausing, and restarting, see our guide to restarting Mounjaro after a break.

Clinical Patient Profiles: Matching the Medication to the Person

Abstract comparison tables are useful but clinical decisions are made for individual patients. Here are six archetypal patient profiles that Slinic clinicians encounter regularly — and what the evidence suggests for each.

Patient 1: Jane, 45, BMI 35, type 2 diabetes, on metformin

Recommendation: Mounjaro. The dual GIP+GLP-1 mechanism produces superior glycaemic control and weight loss in patients with type 2 diabetes. SURMOUNT-2 showed 15.7% average weight loss in this population — still greater than Wegovy in equivalent diabetes trials. Metformin is compatible with both medications; no significant interaction.

Patient 2: Sarah, 52, BMI 31, history of heart attack, no diabetes

Recommendation: Wegovy. The SELECT trial cardiovascular benefit label is clinically meaningful for a patient with established cardiovascular disease. Wegovy is the only weight loss injection with a formal 20% MACE reduction label. Mounjaro’s cardiovascular benefits are likely similar but not yet formally labelled. For this patient, Wegovy is the evidence-backed choice until Mounjaro’s cardiovascular outcomes data is labelled.

Patient 3: Emma, 28, BMI 32, on the combined oral contraceptive pill

Recommendation: Wegovy injection. The absence of an oral contraceptive absorption interaction with the injectable Wegovy makes it the straightforward choice for a patient who does not want to change contraceptive method or use additional barrier contraception. The Wegovy injection bypasses the GI tract and does not affect oral contraceptive absorption.

Patient 4: David, 38, BMI 42, no comorbidities, maximum weight loss priority

Recommendation: Mounjaro. No clinical reason to prefer Wegovy. Mounjaro produces greater average weight loss across all doses and in the direct head-to-head NEJM trial. For a patient whose primary goal is maximum weight loss with no contraindications to Mounjaro, it is the stronger clinical choice.

Patient 5: Patricia, 61, BMI 33, needle phobic, no cardiovascular disease

Recommendation: Wegovy pill (coming soon at Slinic). Needle phobia is a genuine clinical barrier and the Wegovy pill’s MHRA approval on 11 June 2026 offers an evidence-based oral alternative producing 16.6% average weight loss. Patricia can register her interest at Slinic now and start when the pill becomes commercially available within weeks. In the interim, if she can manage the injection, starting Wegovy injection now gives her a head start.

Patient 6: Michael, 47, BMI 37, cost is the primary constraint

Recommendation: Wegovy injection. Approximately £975/year cheaper than Mounjaro at equivalent maintenance doses. Still produces 14.9–20.7% average weight loss depending on dose reached. For a patient for whom cost is genuinely the deciding factor and both medications are clinically appropriate, Wegovy provides excellent clinical value at a meaningfully lower price.

Frequently Asked Questions

NHS Access: Which Medication Is More Accessible?

For patients hoping to eventually access weight loss medication on the NHS, understanding which route is more realistic matters clinically.

NHS Wegovy via NICE TA875 has been available through tier 3 specialist weight management services since 2024 for patients with BMI 35+ and at least one weight-related condition. Waiting times are 12-24 months in most areas — the more accessible NHS route currently.

NHS Mounjaro via NICE TA1026 began its phased GP rollout in June 2025 at a very restrictive starting threshold. Eligibility is expected to widen over 12 years but most patients will not qualify under current criteria. Starting private treatment now does not typically affect your NHS waiting list position.

What About Ozempic? Clearing Up the Confusion

Many patients comparing Mounjaro and Wegovy also research Ozempic. Here is the essential clarification.

Ozempic and Wegovy both contain semaglutide — the same active ingredient — but with different doses and licences. Ozempic is licensed for type 2 diabetes only at a maximum dose of 2mg. It is not licensed for weight management. Wegovy is licensed specifically for obesity treatment at doses up to 7.2mg — this is the correct product if you want semaglutide for weight loss.

Using Ozempic off-label for weight loss means receiving a lower dose than clinically appropriate for obesity treatment from a provider operating outside the licensed indication. Any comparison of Ozempic vs Mounjaro for weight loss is comparing an off-label lower-dose product with a licensed obesity treatment — not an equivalent comparison. At Slinic, we prescribe the right medication for the right indication: Wegovy or Mounjaro for weight management, not Ozempic.

Master Comparison Table: Everything in One Place

All Slinic prices + £4.99 delivery. No subscription. Needles included. Free monthly check-ins. Subject to clinician approval. Prices correct June 2026.

Clinical References

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387(3):205-216.
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021;384(11):989-1002.
3. Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5). NEJM. 2025;393(1):26-36.
4. Wharton S, et al. Once-weekly semaglutide 7.2mg (STEP UP). Lancet Diabetes & Endocrinology. 2025;13(11):949-963.
5. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes (SELECT). NEJM. 2023;389(24):2221-2232.
6. MHRA Drug Safety Update: Tirzepatide (Mounjaro). January 2025.
7. Novo Nordisk. MHRA approval of Wegovy pill (oral semaglutide). 11 June 2026.
8. NICE TA1026 — Tirzepatide for managing overweight and obesity.
9. NICE TA875 — Semaglutide for managing overweight and obesity.

Related Guides & Treatment Pages